Neurocrine Biosciences (NBIX) Non Operating Interest Expenses (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Non Operating Interest Expenses for 9 consecutive years, with $2.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses changed N/A year-over-year to $2.9 million; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (up 54.55% YoY), and the FY2023 full-year result was $4.6 million, down 35.21% from the prior year.
• Non Operating Interest Expenses advanced to $2.9 million in Q2 2026 per NBIX's latest filing, from $1.1 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $2.9 million in Q2 2026 and bottomed at $1.1 million in Q4 2022.
• Historically, Non Operating Interest Expenses has averaged $1.6 million across 4 years, with a median of $1.2 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses plunged 83.33% in 2022, then changed 0.0% in 2023.
• Over 4 years, Non Operating Interest Expenses stood at $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then jumped by 163.64% to $2.9 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $2.9 million, $1.1 million, and $1.1 million for Q2 2026, Q1 2024, and Q4 2023 respectively.